Articles, guides, and regulatory updates from our community.
New research across 85 trials finds incretin-based therapies modestly reduce blood pressure and lower mortality in adults with obesity. Read the evidence.
By Peptide Association Research Team
The GLP-1 revolution has rewritten the rules of obesity treatment. How incretin-based peptide therapies achieve what diet and exercise alone cannot — and what comes next.
By Peptide Association Editorial Team